The use of voxelotorweight-based dosing equivalent to 1,500 mg appears to increase haemoglobin (Hb) levels and decrease clinical markers of haemolysis in patients aged 4–11 years with sickle cell disease (SCD), according to a study presented at EHA 2021.
Patients with relapsed/refractory (R/R) chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL) may have a greater response to zanubrutinib than ibrutinib as well as better progression-free survival (PFS), according to the first interim analysis results of the ALPINE trial.
Mitapivat, an investigational, first-in-class, oral, allosteric pyruvate kinase R (PKR) activator, had clinically meaningful benefit for individuals with PK deficiency regardless of transfusion status, according to the phase III ACTIVATE trials presented at EHA 2021.
Results from the phase III MAIA study showed that the triplet regimen of daratumumab, lenalidomide, and dexamethasone (D-Rd) improved overall survival (OS) compared with lenalidomide plus dexamethasone (Rd) in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM).
Findings from subgroup analyses of the IKEMA trial presented at EHA 2021 aligned with those observed in the overall analysis, further validating the benefits of the isatuximab + carfilzomib-dexamethasone (Isa-Kd) combination regimen for relapsed multiple myeloma (RMM).
In the 5-year updated results of the phase III ECHELON-1 study presented at EHA 2021, a combination of the CD30-directed ADC* brentuximab vedotin and chemotherapy (CT) continued to show potential for individuals with previously untreated stage III/IV classical Hodgkin lymphoma (cHL).
Acalabrutinib with or without obinutuzumab maintains significant progression-free survival (PFS) benefit over the chemoimmunotherapy combination of obinutuzumab plus chlorambucil (O + Clb) through 4 years in treatment-naïve chronic lymphocytic leukaemia (CLL) patients, according to the phase III ELEVATE-TN study presented at EHA 2021.